Ultragenyx Announces First Patients Dosed In Phase 3 Program Evaluating Setrusumab For Treatment Of Osteogenesis Imperfecta
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical Inc. has announced that the first patients have been dosed in a Phase 3 program evaluating Setrusumab for the treatment of Osteogenesis Imperfecta.
July 06, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx's announcement of the first patients being dosed in their Phase 3 program for Setrusumab could potentially impact the company's stock positively in the short term.
The initiation of a Phase 3 program is a significant milestone in drug development. This news indicates progress in Ultragenyx's pipeline, which could positively influence investor sentiment and potentially lead to a short-term increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100